Background and Objective: Obesity is a global health issue closely linked to multiple
cardiovascular and metabolic conditions. The renaming of nonalcoholic fatty liver
disease (NAFLD) to metabolic dysfunctionassociated fatty liver disease (MAFLD) has
sparked discussions about renaming nonalcoholic fatty pancreas disease (NAFPD). This
narrative review explores the potential benefits and challenges of renaming NAFPD
to metabolic dysfunction-associated fatty pancreas disease (MAFPD) and its potential
clinical implications. Methods: The review employs a narrative approach, synthesizing
existing literature and expert opinions to evaluate the rationale behind and the possible
implications of renaming NAFPD to MAFPD. Key Content and Findings: NAFPD is increasingly
recognized worldwide but lacks standardized diagnostic criteria, hindering its independent
classification as a disease. Renaming NAFPD to MAFPD may enhance diagnostic accuracy,
prognostic prediction, and personalized treatment strategies. It may also facilitate
global epidemiological research, data sharing, and collaboration. Major challenges
include establishing uniform diagnostic guidelines for promoting and educating about
the newly proposed terminology. Conclusions: The proposed renaming from NAFPD to MAFPD
may offer promising benefits despite challenges. It may also lead to improved management
and understanding of the disease, potentially benefiting global healthcare strategies
aimed at addressing obesity-related pancreatic complications.
